Stock comparison
Aveanna Healthcare Holdings
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AVAH
Aveanna Healthcare Holdings
Market cap
$1.6B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AVAH | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 38D | 79B | HALO |
| Benjamin Graham | 57D | 83A | HALO |
| Philip Fisher | 35D | 65B | HALO |
| Peter Lynch | 69B | 53D | AVAH |
| Joel Greenblatt | 46D | 40D | AVAH |
| Charlie Munger | 42D | 80C | HALO |
| Terry Smith | 31F | 84A | HALO |
Side-by-side metrics
| Metric | AVAH | HALO |
|---|---|---|
| Market cap | $1.6B | $8.1B |
| P/E (TTM) | 6.3x | 24.0x |
| EV/EBIT | 11.3x | 10.2x |
| ROIC (TTM) | 15.86% | 23.65% |
| Gross margin | 32.67% | 81.24% |
| Net margin | 10.37% | 23.13% |
| Revenue CAGR 5y | 9.73% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 6.3x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AVAH leads on
- P/E (TTM)6.3xvs 24.0x+74%
HALO leads on
- Debt / Equity1.0xvs 6.3x+85%
- Market cap$8.1Bvs $1.6B+80%
- Revenue CAGR 5y33.23%vs 9.73%+71%
- Gross margin81.24%vs 32.67%+60%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.